Livivos
Livivos develops LiverScope, a point-of-care magnetic resonance device that non-invasively measures liver fat for the diagnosis and monitoring of metabolic liver disease. The company serves hepatology clinicians and pharmaceutical companies developing MASH/MASLD therapies, and is currently pursuing FDA 510(k) clearance.
- Company typePrivate
- Founded2018
- HeadquartersSan Diego, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Livivos does
Livivos, Inc. is a San Diego-based medical device company founded in 2018 that has developed LiverScope, a point-of-care magnetic resonance (MR) device designed to non-invasively quantify liver fat for the diagnosis and monitoring of metabolic liver diseases such as MASLD and MASH. The company is small (1–10 employees) and has raised approximately $2M to date, primarily through NIH/NIDDK SBIR grants. Its intended customers are hepatology clinicians at academic medical centers and pharmaceutical companies running clinical trials in MASH/MASLD therapeutics. Named counterparties include UC San Diego Health, Pfizer, Madrigal Pharmaceuticals, Boehringer Ingelheim, and Novo Nordisk.
LiverScope uses single-sided MR with open magnet arrays and RF antennas that sit on a patient's body to measure Proton Density Fat Fraction (MR-PDFF) without ionizing radiation or contrast agents. Validation studies have demonstrated strong correlation with the GE IDEAL IQ MRI gold standard (R² > 0.99 in phantom studies; R² > 0.94 in vivo). The company holds five granted patents, is pursuing FDA 510(k) clearance with a pivotal study underway at UC San Diego, and has been recognized at EASL 2024, ISMRM 2024, MedTech Innovator, ATI Medical Innovation Challenge, and the ADA HealthTech Showcase.
The business model is built on three planned revenue streams: (1) sale of LiverScope devices to hepatology clinics and academic centers once FDA clearance is obtained; (2) clinical-trial-services revenue from pharmaceutical sponsors using the device to quantify liver fat in MASH/MASLD drug development programs; and (3) clinical research services. The device is currently investigational in the US, no public pricing has been disclosed, and any current income is best characterized as exploratory research collaboration rather than commercial sales.
Livivos firmographics
Firmographics- Name
- Livivos
- Legal name
- Livivos, Inc.
- Website
- https://livivos.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Livivos develops LiverScope, a point-of-care magnetic resonance device that non-invasively measures liver fat for the diagnosis and monitoring of metabolic liver disease. The company serves hepatology clinicians and pharmaceutical companies developing MASH/MASLD therapies, and is currently pursuing FDA 510(k) clearance.
- Ownership category
- akta.pro rank
Livivos industry classification
Industry- Product category
- Liver Disease Diagnostic Medical Devices
- NAICS
- Medical Equipment and Supplies Manufacturing (3391), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Hepatology & Liver Disease (HLAKAEAB)
- akta.pro secondary industry
- Remote Patient Monitoring (RPM) Platforms & Services (HLACAPAA)
Keywords
Where Livivos is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Livivos business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Sales: Livivos plans to generate revenue through the sale and placement of LiverScope devices to healthcare providers, hospitals, clinics, and clinical research organizations. The device targets point-of-care settings for liver disease diagnosis and monitoring.
- Pharmaceutical Clinical Trial Services: Revenue generation through partnerships with pharmaceutical companies for drug efficacy clinical trials using LiverScope's quantitative liver fat measurement capabilities.
- Clinical Study Services: Collaboration with academic medical centers and healthcare institutions for NIH-sponsored clinical studies, potentially generating service revenue for device validation and regulatory clearance.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels7 records
Livivos product offering
Product offeringCore offering
Livivos manufactures and commercializes LiverScope, a point-of-care magnetic resonance diagnostic device that quantifies liver fat content using the MR Proton Density Fat Fraction (MR-PDFF) methodology. The device is designed for clinical exam rooms and delivers MRI-quality accuracy in a compact, open, table-based form factor without requiring shielded rooms, contrast agents, or ionizing radiation. It targets pharmaceutical clinical trials, hospital-based liver diagnostics, post-market monitoring, patient triage, and preventive medicine screening.
Product overview
Livivos offers a single unified product—the LiverScope® device—which is the world's only point-of-care steatosis quantification technology. The LiverScope® provides rapid, non-invasive liver fat measurement using Magnetic Resonance Proton Density Fat Fraction (MR-PDFF) methodology, delivering MRI-quality diagnostic accuracy in a portable, open-design format suitable for point-of-care settings. The device targets pharmaceutical clinical trials, post-market monitoring, patient triage, and preventive medicine applications.
Differentiator
Problem solved
Functional benefit
Brands
- LiverScope: Point-of-care magnetic resonance device for liver disease diagnosis, measuring Proton Density Fat Fraction (MR-PDFF).
- MR-PDFF
Products and services
- LiverScope The LiverScope is a point-of-care magnetic resonance diagnostic device that quantifies liver fat using the MR Proton Density Fat Fraction (MR-PDFF) methodology. It is designed for healthcare institutions and pharmaceutical companies conducting liver disease (NAFLD/NASH/MASH) diagnosis, patient triage, post-market monitoring, and preventive medicine screening. The device provides MRI-quality accuracy in an open, table-based form factor usable in standard clinical exam rooms.
Quantifiable outcome
- R-squared > 0.99 correlation between LiverScope PDFF and certified MRI PDFF values in phantom studies
- +1 more outcomes
Companies that use Livivos
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles2 records
Livivos technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Livivos partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- UC San DiegocoreCollaborative partnership with UC San Diego's Liver Imaging Group for clinical validation studies of LiverScope. NIH-sponsored pivotal study underway at UCSD. Partnership includes Dr. Claude Sirlin (Principal Medical Advisor), Dr. Eduardo Grunvald (Principal Investigator), and Dr. Rohit Loomba as grant collaborators.
- AASLDcoreActive participation in AASLD The Liver Meeting 2024 in San Diego, the premier conference on liver diseases, where LiverScope was showcased to hepatology specialists.
- Madrigal PharmaceuticalsminorDiscussions held at EASL 2024 regarding potential collaborative studies involving LiverScope for MASH drug clinical trials.
- Boehringer IngelheimminorMetabolic associated steatohepatitis (MASH) drug activity developer; exploratory discussions at EASL 2024 for collaborative studies.
- Novo NordiskminorObesity and MASH drug developer; discussions held at EASL 2024 regarding collaborative studies for liver disease diagnostics.
- MASH-TAGminorConference partnership for 2025 MASH-TAG Annual Conference in Park City, Utah, bringing together clinicians, academia, and pharmaceutical industry to discuss liver disease therapeutics.
- PfizercoreUsage agreement signed October 2022 for Pfizer to conduct investigation of LiverScope's Proton Density Fat Fraction (PDFF) measurement capabilities for fatty liver disease assessment over a six-month period.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
Livivos competitors and assessment
Company assessmentDirect peers
- Echosens: Echosens manufactures FibroScan, the leading point-of-care non-invasive liver diagnostic (primarily elastography for fibrosis, with steatosis capabilities). It is the most directly comparable commercial-stage competitor to Livivos' LiverScope, sharing the same point-of-care hepatology positioning, CPT-coded reimbursement strategy, and target customer base of hepatologists and clinical trial sponsors.
- Perspectum: Perspectum offers LiverMultiScan, an MRI-based multiparametric liver diagnostic used in clinical trials and tertiary care for steatosis, iron, and fibrosis. It competes with LiverScope for the same pharma clinical-trial endpoint budget and the same hepatology KOL relationships, although Perspectum is software-on-existing-MRI rather than a portable device.
Broad incumbents
- GE HealthCare: GE HealthCare's IDEAL IQ MRI PDFF sequence is the reference standard used to clinically validate LiverScope (R² > 0.94 correlation). As the dominant installed-base MRI vendor, GE is both a validation benchmark and a potential competitive threat if it bundles or extends its liver quantification software suite to displace standalone point-of-care devices.
- Siemens Healthineers: Siemens Healthineers is a major MRI OEM whose liver imaging packages (e.g., LiverLab) compete with LiverScope at academic medical centers and pharma trial sites. As a broad incumbent in diagnostic imaging, it represents both a potential channel partner and a competitive threat if it integrates more advanced quantitative liver tools.
- Philips Healthcare: Philips is a global MRI and diagnostic imaging incumbent with liver quantification capabilities on its MRI platforms. Comparable to Livivos as a broad incumbent in liver imaging; relevant for understanding competitive landscape and potential OEM partnership pathways.
- Hologic: Hologic is a women's health-focused diagnostics and medical device company. While not a direct liver competitor, it is comparable as a specialized medical-device company commercializing point-of-care diagnostic hardware to clinical specialists, with similar regulatory, sales, and reimbursement dynamics.
- Canon Medical Systems: Canon Medical manufactures MRI and ultrasound systems used in liver imaging. As a broad incumbent with quantitative imaging tools, it is comparable to Livivos in serving the hepatology imaging workflow and represents both a competitive and partnership consideration for point-of-care diagnostics.
Emerging players
- Resoundant: Resoundant develops MR Elastography (MRE) technology for non-invasive liver fibrosis assessment, deployed on existing MRI scanners. It overlaps with LiverScope in addressing the same hepatology disease-staging workflow and competes for the same pharma clinical-trial endpoint share, though via a software/add-on model rather than a portable hardware device.
Others
- CymaBay Therapeutics (acquired by Gilead): CymaBay was a MASH/NAFLD drug developer (acquired by Gilead in 2024) and exemplifies the pharmaceutical end-customer category Livivos targets with LiverScope-based trial endpoints. Relevant as a representative pharma customer/peer for understanding the clinical-trial endpoint procurement dynamic.
- Madrigal Pharmaceuticals: Madrigal Pharmaceuticals developed Rezdiffra, the first FDA-approved MASH therapy. Already engaged with Livivos at EASL 2024 regarding collaborative LiverScope studies, Madrigal is both a current partner and a representative peer for understanding the pharma demand-side of point-of-care liver diagnostics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Livivos social profiles
Digital presenceLivivos financial estimates
Financial estimateRevenue estimate
Valuation estimate
Livivos leadership team
Management profileNumber of profiles
Profiles6 records
Livivos funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Livivos M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Livivos
What does Livivos do?
Livivos manufactures and commercializes LiverScope, a point-of-care magnetic resonance diagnostic device that quantifies liver fat content using the MR Proton Density Fat Fraction (MR-PDFF) methodology. The device is designed for clinical exam rooms and delivers MRI-quality accuracy in a compact, open, table-based form factor without requiring shielded rooms, contrast agents, or ionizing radiation. It targets pharmaceutical clinical trials, hospital-based liver diagnostics, post-market monitoring, patient triage, and preventive medicine screening.
Is Livivos a public or private company?
Livivos is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Livivos founded?
Livivos was founded in 2018. It employs 1 to 10 people.
Where is Livivos based?
Livivos is headquartered in San Diego, United States, in the North America region.
How does Livivos make money?
Three revenue lines are on record. Medical Device Sales are the primary driver. The others are pharmaceutical Clinical Trial Services and clinical Study Services.
Who are Livivos's main competitors?
Direct peers on record are Echosens and Perspectum. Broad incumbents are GE HealthCare, Siemens Healthineers, Philips Healthcare, Hologic and Canon Medical Systems. Resoundant is listed as an emerging player. Others are CymaBay Therapeutics (acquired by Gilead) and Madrigal Pharmaceuticals.
Does Livivos have an API?
No public API is recorded for Livivos.
What industry is Livivos in?
Livivos's product category is Liver Disease Diagnostic Medical Devices. Its primary akta.pro industry code is HLAKAEAB, Hepatology & Liver Disease, with a secondary code of HLACAPAA, Remote Patient Monitoring (RPM) Platforms & Services. Its NAICS code is 3391 and its SIC code is 3841.